We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

45 hedge funds and large institutions have $85.5M invested in VanEck Pharmaceutical ETF in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 44 → 45 (+1)

4.66% less ownership

Funds ownership: 44.28% → 39.62% (-4.7%)

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

30% less capital invested

Capital invested by funds: $122M → $85.5M (-$36.7M)

Holders
45
Holders Change
+1
Holders Change %
+2.27%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
10
Reduced
14
Closed
8
Calls
$496K
Puts
–
Net Calls
+$496K
Net Calls Change
+$1.54M

Top Buyers

Rank Fund Capital Flow
1
BCI
Brinker Capital Investments
Pennsylvania
+$8.9M
2
Citadel Advisors
Citadel Advisors
Florida
+$3.43M
3
Cerity Partners
Cerity Partners
New York
+$1.28M
4
FA
Fortis Advisors
Pennsylvania
+$759K
5
NL
NVWM LLC
Pennsylvania
+$482K

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$12.1M
2
MIH
Meitav Investment House
Israel
-$6.61M
3
Goldman Sachs
Goldman Sachs
New York
-$6.06M
4
RJA
Raymond James & Associates
Florida
-$5.09M
5
SG Americas Securities
SG Americas Securities
New York
-$3.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
ASN
26
Advisory Services Network
Georgia
$43K +$61 +1 +0.1%
MIM
27
Macroview Investment Management
Maryland
$42K – – –
HCM
28
Highlander Capital Management
New Jersey
$41K – – –
AG
29
Advisor Group
Arizona
$39K -$20.3K -335 -32%
FDCDDQ
30
Federation des caisses Desjardins du Quebec
Quebec, Canada
$32.9K +$12.1K +200 +50%
LWM
31
Liberty Wealth Management
California
$30K +$33.3K +550 New
CFGS
32
Concourse Financial Group Securities
Alabama
$27K – – –
Citigroup
33
Citigroup
New York
$19K -$12.1M -200,000 -100%
WWM
34
Willingdon Wealth Management
North Carolina
$18K – – –
JCM
35
Jacobi Capital Management
Pennsylvania
$11K – – –
ADL
36
Asset Dedication LLC
California
$9K – – –
CWA
37
Clarus Wealth Advisors
Arizona
$5K – – –
FANJ
38
Financial Architects (New Jersey)
New Jersey
$4K +$61 +1 +1%
AIM
39
Anchor Investment Management
South Carolina
$3.18K – – –
William Blair & Company
40
William Blair & Company
Illinois
$2K -$9.09K -150 -77%
BFEC
41
Benjamin F. Edwards & Company
Missouri
$1K – – –
ST
42
Sageworth Trust
Pennsylvania
$1K +$787 +13 New
Simplex Trading
43
Simplex Trading
Illinois
$1K +$1.57K +26 New
GT
44
Glenmede Trust
Pennsylvania
$54 +$60.6K +1,000 New
SG Americas Securities
45
SG Americas Securities
New York
– -$3.22M -50,000 Closed
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
– -$1.31M -21,708 Closed
JIP
47
Jaffetilchin Investment Partners
Florida
– -$490K -7,619 Closed
Janney Montgomery Scott
48
Janney Montgomery Scott
Pennsylvania
– -$360K -5,601 Closed
Jane Street
49
Jane Street
New York
– -$343K -5,334 Closed
FPCM
50
Financial Partners Capital Management
New York
– -$214K -3,325 Closed
1
2
3

PPH Hedge Fund Activity: Q4 2018 in Review

45 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2018, worth a combined $85.5M — down 30% from $122M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PPH positions and 8 closed out — a net gain of 1 holder — while 10 added to existing stakes and 14 trimmed.

The largest buyer was Brinker Capital Investments, opening a new position worth an estimated $8.9M. The largest seller was Citigroup, cutting an estimated $12.1M.

  • 45 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2018, up from 44 in Q3 2018.
  • Funds reported $85.5M of VanEck Pharmaceutical ETF stock for Q4 2018, down 30% quarter-over-quarter.
  • 9 funds opened new VanEck Pharmaceutical ETF positions in Q4 2018 and 8 closed out, a net change of +1 holder.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2018 was Brinker Capital Investments, an estimated $8.9M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2018 was Citigroup, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2018.